Welcome to our dedicated page for GNCA news (Ticker: GNCA), a resource for investors and traders seeking the latest updates and insights on GNCA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GNCA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GNCA's position in the market.
Genocea Biosciences (NASDAQ: GNCA) will have its CEO, Chip Clark, participate in a fireside chat at the B. Riley Securities’ Virtual Oncology Investor Conference. This event is scheduled for January 21, 2021, from 11:00 am to 11:30 am ET. Investors can access the live webcast on Genocea's website, where it will also be archived for approximately 90 days. Genocea focuses on developing personalized cancer immunotherapies using its ATLAS™ platform to optimize neoantigens and exclude immunosuppressive Inhibigens™.
Genocea Biosciences (NASDAQ: GNCA) will present a corporate overview at the H.C. Wainwright Virtual BioConnect Conference from January 11-14, 2021. Chip Clark, CEO, will lead the presentation, with a webcast available on their investor website starting January 11. Post-conference, the presentation will be archived for approximately 90 days. Genocea focuses on developing personalized cancer immunotherapies using its ATLAS™ platform to identify neoantigens that optimize immune responses against tumors. To learn more, visit their website.
Genocea Biosciences (NASDAQ: GNCA) will present a corporate overview at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, at 8:40 a.m. ET. Chip Clark, the CEO, will lead the presentation, which can be accessed via live webcast on their investor relations page. Genocea is focused on developing personalized cancer immunotherapies using its ATLAS™ platform, which profiles T cell responses to optimize neoantigen inclusion. The company is advancing two key programs: GEN-009 and GEN-011. A replay of the presentation will be available for 90 days.
Genocea Biosciences (GNCA) presented promising data on its neoantigen immunotherapies at the SITC Annual Meeting. Their GEN-009 trial showed that three out of nine patients receiving PD-1 inhibitors exhibited reductions in tumor volume, achieving two partial responses and one complete response. Among CPI-resistant patients, five of seven displayed disease stabilization. The company also introduced GEN-011, a next-generation therapy, which demonstrated 100% manufacturing success and targeted over 90% of neoantigens, excluding inhibitory peptides. These findings bolster Genocea's approach to cancer treatment.
Genocea Biosciences, developing neoantigen immunotherapies, will host an investor call on November 9 at 8:30 a.m. EST. The call aims to discuss clinical and immune response data related to their GEN-009 trial, with insights from CEO Chip Clark and CMO Thomas Davis. The 35th Annual Meeting of The Society for Immunotherapy of Cancer will feature presentations of their findings. Interested parties can join via phone or webcast, and recordings will be available post-call.
Genocea Biosciences (NASDAQ: GNCA) announced the initiation of its GEN-011 Phase 1/2a clinical trial, following FDA approval of its IND application. The trial will evaluate safety and clinical activity in patients who have previously failed standard therapies, enrolling up to 24 participants. The company also reported promising follow-up data from its GEN-009 trial, showing tumor reductions or stable outcomes in all patients presented. With a cash position of $87.6 million as of September 30, 2020, Genocea is well-funded to advance its clinical programs through mid-2022.
Genocea Biosciences (NASDAQ: GNCA) will hold its third quarter 2020 financial results and corporate update on October 29, 2020, at 8:30 a.m. EDT. Participants can join by calling (844) 826-0619 domestically or (315) 625-6883 internationally, using conference ID 5951388. A live webcast is available on the Genocea investor relations page. A replay will be accessible post-event for 90 days. Genocea aims to develop personalized cancer immunotherapies using its ATLAS™ platform to identify effective neoantigens.
Genocea Biosciences (NASDAQ: GNCA) announced its presentation schedule for the 35th Annual Meeting of The Society for Immunotherapy of Cancer (SITC 2020) happening virtually from November 9-14. Key highlights include:
- Safety and activity data from the GEN-009 Phase 1/2a trial.
- Introduction of GEN-011, a T cell therapy addressing limitations of existing treatments.
- Insights on Inhibigens identified by the ATLAS platform.
Posters will be available on November 9 at 8 a.m. ET, showcasing new data and advancements in their immunotherapy developments.
Genocea Biosciences (NASDAQ: GNCA) announced the FDA's acceptance of their IND application for GEN-011, an innovative adoptive T cell therapy targeting neoantigens. This allows for the initiation of a Phase 1/2a clinical study in patients who have not responded to standard checkpoint therapies. The trial will assess safety, T cell proliferation, and clinical activity. Genocea aims to enroll up to 24 patients, with plans to utilize its ATLAS™ platform to optimize treatment efficacy. The company believes GEN-011 holds potential advantages in accessibility and cost-effectiveness.
On September 17, 2020, Genocea Biosciences (NASDAQ: GNCA) presented new clinical data from its GEN-009 Phase 1/2a trial at the ESMO Virtual Congress. The results showed that 100% of evaluated patients exhibited immune responses to neoantigens, with tumor responses indicating potential benefits of combining GEN-009 with standard PD-1 inhibitors. Notably, three patients demonstrated RECIST responses, and no significant side effects were reported. The company anticipates sharing more comprehensive data later this year as it explores GEN-009's role in enhancing cancer immunotherapy.
